Aeterna Zentaris (NASDAQ:AEZS) has made a significant change in its executive suite and boardroom. David Dodd is now the company's chief executive and a member of its board of directors. He succeeds Juergen Engel. The firm did not provide the reasons for the succession.

Dodd has been in the pharmaceutical and biotech industries for more than 35 years. He was CEO and chairman of BioReliance, now a unit of Sigma-Aldrich. He also served in various executive capacities for companies such as Serologicals (now a subsidiary of Millipore) and Solvay Pharmaceuticals, among other prominent firms in the industry.